Single-Cell Transcriptomics Reveals Riluzole as an Osteoarthritis Candidate Drug via OB-NE Signaling Modulation and CTSS/NOS1 Inhibition

Introduction: Osteoarthritis (OA) is a degenerative joint disease involving multiple cell types, yet the role of osteoblast (OB)-immune cell interactions remains poorly understood. Methods: Single-cell RNA sequencing of human femoral head tissue was employed in this study, followed by integrated analysis using bioinformatics tools such as differential expression analysis, enrichment analysis and cell communication analysis. A network proximity-based drug repositioning approach was employed to identify potential drug candidates. Mendelian randomization (MR) analysis was used to explore the causal relationship between drug targets and OA. In vivo, a triclocarban (TCC)-induced zebrafish OA model was treated with selected drugs, and transcriptomic sequencing, network pharmacology and molecular docking were performed to identify potential drug targets. Results: =0.027). In zebrafish OA models, riluzole treatment significantly reduced joint degeneration and downregulated CTSS, NOS1 and key components of the MAPK/ERK pathway. Molecular docking studies demonstrated strong binding affinity of riluzole to CTSS and NOS1, suggesting that inhibition of these targets may underlie its therapeutic action via suppression of MAPK/ERK suppression. Conclusion: This study highlights riluzole as a promising repositioned drug for OA. Limitations of this study include the relatively small sample size and the need for further translational validation in clinical settings.